Reny Aniline
Senior Director - BioPharma Business Development Natera
Seminars
Thursday 8th October 2026
Accelerate Early Phase Drug Development with MIIRA, Natera’s longitudinal ctDNA & Multi-Modal Real-World Data Platform
11:00 am
- Real-world comparator benchmarking for early-phase decision making: MIIRA enables the design and analysis of real-world patient control arms to establish molecular response benchmarks for comparison against Phase 1 and 2 investigational ctDNA data. We will walk through a live, blinded case study of a biotech partnering with Natera to develop a real-world comparator cohort in colorectal cancer
- De-risking MRD-guided trial designs: MRD-guided trial designs, including IMvigor011 and ALPHA3, are reshaping treatment paradigms across oncology. Partners are using MIIRA to analyze real-world MRD patterns, define addressable ITT populations, and enroll patients in real time in Phase 3 trials based on commercial Signatera data paired with EMR history
